The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

BMC Cancer

Table 2 Analysis of overall survival time by clinical factors

Characteristics	Patients n (%)	OS (months)	Univariate analysis	Multivariate analysis
Characteristics	Patients n (%)	OS (months)	P	HR (95 % CI)	P
Age (years)
≥ 75	62 (25)	15.1	0.005	1.35 (0.90–1.99)	0.150
< 75	184 (75)	24.2	0.005	Reference	0.150
Sex
Male	154 (63)	19.1	0.279	1.30 (0.87–1.97)	0.204
Female	92 (37)	26.2	0.279	Reference	0.204
Smoking status
Never	101 (41)	23.8	0.742	0.91 (0.64–1.36)	0.636
Current or former	145 (59)	19.3	0.742	Reference	0.636
ECOG PS
0 or 1	184 (75)	26.5	<0.001	0.42 (0.29–0.62)	<0.001
2–4	62 (25)	8.8	<0.001	Reference	<0.001
EGFR status
Mutated	100 (41)	31.1	0.001	0.41 (0.29–0.57)	<0.001
WT or uninvestigated	146 (59)	16.9	0.001	Reference	<0.001
Stage
IIIB	26 (11)	43.9	0.016	0.38 (0.21–0.64)	<0.001
IV	220 (89)	20.2	0.016	Reference	<0.001
Serum CEA
Negative	83 (34)	20.4	0.985	0.79 (0.56–1.11)	0.180
Positive	163 (66)	21.8	0.985	Reference	0.180
Serum CYFRA 21-1
Negative	91 (37)	31.8	<0.001	0.47 (0.32–0.66)	<0.001
Positive	155 (63)	16.9	<0.001	Reference	<0.001
Serum CA 19-9
Negative	170 (69)	26.2	<0.001	0.60 (0.43–0.85)	0.005
Positive	76 (31)	12.5	<0.001	Reference	0.005
Chemotherapy
Platinum doublet	170 (69)	25.0	<0.001	0.64 (0.42–0.97)	0.034
Others	76 (31)	14.2	<0.001	Reference	0.034

CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CI confidence interval, CYFRA 21-1 cytokeratin 19 fragments, ECOG PS Eastern Cooperative Oncology Group Performance Status, EGFR epidermal growth factor receptor gene, WT wild-type, HR hazard ratio, OS overall survival

ISSN: 1471-2407